The trial will be conducted in the Democratic Republic of the Congo in partnership with Emergent BioSolutions.

Emergent BioSolutions (EBS) announced that brincidofovir will be included in a clinical trial conducted and sponsored by Panther, under the ...

Concurrently, Emergent BioSolutions announced that brincidofovir (brand name Tembexa for smallpox treatment) will be included ...

PANTHER to conduct clinical trial under the leadership of Africa Centres for Disease Control and PreventionGAITHERSBURG, Md., Nov. 06, 2024 ...

Emergent BioSolutions raised its revenue guidance and dropped a going concern warning. Its CEO is billing this next chapter ...

Emergent Biosolutions (NYSE:EBS) stock rose 14% post-market Wednesday after the company raised the lower end of its revenue ...

Shares of Emergent Biosolutions climbed after the company reported an increase in revenue and swung to a profit in the third quarter. The stock was up 28% to $11.81 in Thursday afternoon trading.

Emergent BioSolutions' Q3 earnings report drives 20% surge in share price, reflecting market optimism. See why award a ...

Nov. 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that brincidofovir (brand name TEMBEXA®) will be included in a clinical trial conducted and sponsored by ...

Emergent BioSolutions appointed Dr. Simon Lowry as chief medical officer and head of research and development. CureVac named ...

GAITHERSBURG, Md. - Emergent BioSolutions Inc. (NYSE:EBS), a company specializing in public health threat solutions, has announced the appointment of Dr. Simon Lowry as chief medical officer and ...

On a per-share basis, the Gaithersburg, Maryland-based company said it had profit of $2.06. Earnings, adjusted for non-recurring gains, were $1.37 per share. The biopharmaceutical company posted ...